



February 3, 2014

OFFICERS

The Hon. John Edward Porter, Chair
The Hon. Michael N. Castle, Vice Chair
Mary Woolley, President
Larry J. Shapiro, MD, Secretary
Lucinda Maine, PhD, RPh, Treasurer

BOARD MEMBERS

Tenley E. Albright, MD
Georges C. Benjamin, MD
Nancy Brown
Susan Dentzer
Victor J. Dzau, MD
Joseph M. Feczko, MD
Jay A. Gershen, DDS, PhD
William N. Hait, MD, PhD
Mary J.C. Hendrix, PhD
Martha N. Hill, PhD, RN
Harry Johns
Jackie Lovelace Johnson
Evan Jones
Elizabeth Baker Keffer
The Hon. Patrick J. Kennedy
Debra R. Lappin, JD
Alan I. Leshner, PhD
James L. Madara, MD
Mark McClellan, MD, PhD
The Hon. Kweisi Mfume
Elizabeth G. Nabel, MD
Herbert Pardes, MD
Sudip S. Parikh, PhD
Amy Comstock Rick, JD
John R. Seffrin, PhD
Laing Rogers Sisto
Jack T. Watters, MD
Keith R. Yamamoto, PhD
Elias A. Zerhouni, MD

The Honorable Barbara Mikulski
Chairwoman
Committee on Appropriations
United States Senate

The Honorable Richard Shelby
Ranking Member
Committee on Appropriations
United State Senate

The Honorable Mark Pryor
Chairman
Subcommittee on Agriculture, Rural
Development and Food & Drug
Administration
United States Senate

The Honorable Roy Blunt
Ranking Member
Subcommittee on Agriculture, Rural
Development and Food & Drug
Administration
United States Senate

Dear Chairs Mikulski, Rogers, Pryor and Arderholt and Ranking Members
Shelby, Lowey, Blunt, and Farr:

On behalf of Research!America, the nation's largest not-for-profit public education and advocacy alliance working to make research to improve health a higher national priority, I would like to thank you for the funding increase you provided to the U.S. Food and Drug Administration (FDA) in the Consolidated Appropriations Act of 2014.

Among its many contributions to human health and safety, FDA bears the formidable responsibility of ensuring that safe and effective medical treatments reach patients as soon as possible. Because lives literally hang in the balance, maximizing the efficiency and accuracy of FDA's work in this area is absolutely crucial. It speaks to your committed stewardship of the public health that you not only provided increased resources for this function, but compensated for the 2013 sequestration of FDA user fees.

While we hope that future appropriations measures will also assign top priority to funding for the National Institutes of Health and other agencies crucial to accelerated medical progress, we truly appreciate your leadership and the

The Honorable Hal Rogers
Chairman
Committee on Appropriations
United States House of Representatives

The Honorable Nita Lowey
Ranking Member
Committee on Appropriations
United State House of Representatives

The Honorable Robert Aderholt
Chairman
Subcommittee on Agriculture, Rural
Development and Food & Drug
Administration
United States House of Representatives

The Honorable Sam Farr
Ranking Member
Subcommittee on Agriculture, Rural
Development and Food & Drug
Administration
United States House of Representatives

1101 King Street
Suite 520
Alexandria, VA 22314-2960

P 703.739.2577


F 703.739.2372

E info@researchamerica.org

www.researchamerica.org

determination with which you pursued, and achieved, the prioritization of discretionary funding enabled by regular order.

Sincerely,

A handwritten signature in cursive script that reads "Mary Woolley". The signature is written in black ink and is positioned above the printed name and title.

Mary Woolley
President and CEO